| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
EMTEK (Shenzhen) Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥20.00 |
| 52 Week High | CN¥31.02 |
| 52 Week Low | CN¥17.11 |
| Beta | 0.063 |
| 11 Month Change | -12.89% |
| 3 Month Change | -15.67% |
| 1 Year Change | -33.79% |
| 33 Year Change | 6.27% |
| 5 Year Change | n/a |
| Change since IPO | -10.69% |
Recent News & Updates
Shareholder Returns
| 300938 | CN Professional Services | CN Market | |
|---|---|---|---|
| 7D | -2.6% | -2.8% | -2.7% |
| 1Y | -33.8% | -27.1% | -17.4% |
Return vs Industry: 300938 underperformed the CN Professional Services industry which returned -27.1% over the past year.
Return vs Market: 300938 underperformed the CN Market which returned -17.4% over the past year.
Price Volatility
| 300938 volatility | |
|---|---|
| 300938 Average Weekly Movement | 6.7% |
| Professional Services Industry Average Movement | 8.3% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in CN Market | 10.1% |
| 10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 300938's share price has been volatile over the past 3 months.
Volatility Over Time: 300938's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 1,415 | Jianjun Wang | www.emtek.com.cn |
EMTEK (Shenzhen) Co., Ltd. operates as a third-party testing institution in China. The company provides schedule site testing and certification validation, as well as technical services and solutions, such as testing, certification, and standard research and development services. It serves customers in the daily consumer goods, new energy, industrial products and components, life science, etc. The company was founded in 2000 and is headquartered in Shenzhen, China.
EMTEK (Shenzhen) Co., Ltd. Fundamentals Summary
| 300938 fundamental statistics | |
|---|---|
| Market cap | CN¥3.14b |
| Earnings (TTM) | CN¥173.12m |
| Revenue (TTM) | CN¥709.62m |
18.2x
P/E Ratio4.4x
P/S RatioIs 300938 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300938 income statement (TTM) | |
|---|---|
| Revenue | CN¥709.62m |
| Cost of Revenue | CN¥295.26m |
| Gross Profit | CN¥414.36m |
| Other Expenses | CN¥241.23m |
| Earnings | CN¥173.12m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.10 |
| Gross Margin | 58.39% |
| Net Profit Margin | 24.40% |
| Debt/Equity Ratio | 39.5% |
How did 300938 perform over the long term?
See historical performance and comparison